Role of mutations in dihydrofolate reductase DfrA (Rv2763c) and thymidylate synthase ThyA (Rv2764c) in Mycobacterium tuberculosis drug resistance

Antimicrobial Agents and Chemotherapy

Volumn 54, Issue 10, 2010, Pages 4522-4523

  Köser, Claudio U ^a   Veerapen Pierce, Richard N ^a   Summers, David K ^a   Archer, John A C ^b  

^a UNIVERSITY OF CAMBRIDGE   (United Kingdom)

^b KING ABDULLAH UNIVERSITY OF SCIENCE AND TECHNOLOGY   (Saudi Arabia)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIMALARIAL AGENT; COTRIMOXAZOLE; DIHYDROFOLATE REDUCTASE; ETHIONAMIDE; ISONIAZID; METHOTREXATE; THYMIDYLATE SYNTHASE;

AMINO ACID SUBSTITUTION; ANTIBIOTIC RESISTANCE; CROSS RESISTANCE; DRUG RESISTANT TUBERCULOSIS; DRUG SENSITIVITY; GENE MUTATION; HUMAN; LETTER; MYCOBACTERIUM TUBERCULOSIS; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL;

ANTITUBERCULAR AGENTS; MUTATION; MYCOBACTERIUM TUBERCULOSIS; TETRAHYDROFOLATE DEHYDROGENASE; THYMIDYLATE SYNTHASE; TUBERCULOSIS, MULTIDRUG-RESISTANT;

EID: 77957328041     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.00422-10     Document Type: Letter

References (20)

1. Argyrou, A., M. Vetting, B. Aladegbami, and J. Blanchard. 2006. Mycobacterium tuberculosis dihydrofolate reductase is a target for isoniazid. Nat. Struct. Mol. Biol. 13:408-413.
2. Baca, A., R. Sirawaraporn, S. Turley, W. Sirawaraporn, and W. Hol. 2000. Crystal structure of Mycobacterium tuberculosis 7,8-dihydropteroate synthase in complex with pterin monophosphate: new insight into the enzymatic mechanism and sulfa-drug action. J. Mol. Biol. 302:1193-1212.
3. Besier, S., A. Ludwig, K. Ohlsen, V. Brade, and T. Wichelhaus. 2007. Molecular analysis of the thymidine-auxotrophic small colony variant phenotype of Staphylococcus aureus. Int. J. Med. Microbiol. 297:217-225.
4. Besier, S., J. Zander, B. C. Kahl, P. Kraiczy, V. Brade, and T. A. Wichelhaus. 2008. The thymidine-dependent small-colony-variant phenotype is associated with hypermutability and antibiotic resistance in clinical Staphylococcus aureus isolates. Antimicrob. Agents Chemother. 52:2183-2189.
5. Chatterjee, I., A. Kriegeskorte, A. Fischer, S. Deiwick, N. Theimann, R. Proctor, G. Peters, M. Herrmann, and B. Kahl. 2008. In vivo mutations of thymidylate synthase (encoded by thyA) are responsible for thymidine dependency in clinical small-colony variants of Staphylococcus aureus. J. Bacteriol. 190:834-842.
6. Forgacs, P., N. Wengenack, L. Hall, S. Zimmerman, M. Silverman, and G. Roberts. 2009. Tuberculosis and trimethoprim-sulfamethoxazole. Antimicrob. Agents Chemother. 53:4789-4793.
7. Gengenbacher, M., T. Xu, P. Niyomrattanakit, G. Spraggon, and T. Dick. 2008. Biochemical and structural characterization of the putative dihydropteroate synthase ortholog Rv1207 of Mycobacterium tuberculosis. FEMS Microbiol. Lett. 287:128-135.
8. Ho, Y., Y. Sun, S. Wong, and A. Lee. 2009. Contribution of dfrA and inhA mutations to the detection of isoniazid-resistant Mycobacterium tuberculosis isolates. Antimicrob. Agents Chemother. 53:4010-4012.
9. Huovinen, P. 2001. Resistance to trimethoprim-sulfamethoxazole. Clin. Infect. Dis. 32:1608-1614.
10. Huovinen, P., L. Sundström, G. Swedberg, and O. Sköld. 1995. Tri-methoprim and sulfonamide resistance. Antimicrob. Agents Chemother. 39:279-289.
11. Li, R., R. Sirawaraporn, P. Chitnumsub, W. Sirawaraporn, J. Wooden, F. Athappilly, S. Turley, and W. G. J. Hol. 2000. Three-dimensional structure of M. tuberculosis dihydrofolate reductase reveals opportunities for the design of novel tuberculosis drugs. J. Mol. Biol. 295:307-323.
12. Mathys, V., R. Wintjens, P. Lefevre, J. Bertout, A. Singhal, M. Kiass, N. Kurepina, X. Wang, B. Mathema, A. Baulard, B. Kreiswirth, and P. Bifani. 2009. Molecular genetics of para-aminosalicylic acid resistance in clinical isolates and spontaneous mutants of Mycobacterium tuberculosis. Antimicrob. Agents Chemother. 53:2100-2109.
13. Rengarajan, J., C. M. Sassetti, V. Naroditskaya, A. Sloutsky, B. R. Bloom, and E. J. Rubin. 2004. The folate pathway is a target for resistance to the drug para-aminosalicylic acid (PAS) in mycobacteria. Mol. Microbiol. 53:275-282.
14. Sendi, P., and R. Proctor. 2009. Staphylococcus aureus as an intracellular pathogen: the role of small colony variants. Trends Microbiol. 17:54-58.
15. Suling, W., R. Reynolds, E. Barrow, L. Wilson, J. Piper, and W. Barrow. 1998. Susceptibilities of Mycobacterium tuberculosis and Mycobacterium avium complex to lipophilic deazapteridine derivatives, inhibitors of dihydrofolate reductase. J. Antimicrob. Chemother. 42:811-815.
16. Vickers, A., N. Potter, C. Fishwick, I. Chopra, and A. O'Neill. 2009. Analysis of mutational resistance to trimethoprim in Staphylococcus aureus by genetic and structural modelling techniques. J. Antimicrob. Chemother. 63:1112-1117.
17. Vilchèze, C., and W. J. Jacobs. 2007. The mechanism of isoniazid killing: clarity through the scope of genetics. Annu. Rev. Microbiol. 61:35-50.
18. Young, L. 2009. Reconsidering some approved antimicrobial agents for tuberculosis. Antimicrob. Agents Chemother. 53:4577-4579.
19. Yuvaniyama, J., P. Chitnumsub, S. Kamchonwongpaisan, J. Vanichtanankul, W. Sirawaraporn, P. Taylor, M. Walkinshaw, and Y. Yuthavong. 2003. Insights into antifolate resistance from malarial DHFR-TS structures. Nat. Struct. Biol. 10:357-365.
20. Zhang, Z., Y. Zhao, Z. Li, H. Jia, Y. Liu, X. Chen, Z. Liu, B. Du, A. Xing, and Y. Ma. 2007. Mutations in the thymidylate synthase gene is a major mechanism in the para-aminosalicylic acid resistance of M. tuberculosis. Zhonghua Jie He He Hu Xi Za Zhi 30:683-685. (In Chinese.)